JP6427164B2 - カリウムイオンチャネル阻害剤としてのフタラジン - Google Patents
カリウムイオンチャネル阻害剤としてのフタラジン Download PDFInfo
- Publication number
- JP6427164B2 JP6427164B2 JP2016500926A JP2016500926A JP6427164B2 JP 6427164 B2 JP6427164 B2 JP 6427164B2 JP 2016500926 A JP2016500926 A JP 2016500926A JP 2016500926 A JP2016500926 A JP 2016500926A JP 6427164 B2 JP6427164 B2 JP 6427164B2
- Authority
- JP
- Japan
- Prior art keywords
- minutes
- alkyl
- substituted
- phenyl
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *Cc1ccccn1 Chemical compound *Cc1ccccn1 0.000 description 2
- KBUQCQMKINPEAI-UHFFFAOYSA-N CC(C)(C)NS(c1cc(-c2c(cccc3-c4ccccc4N4Cc5ccccn5)c3c4nn2)cnc1)(=O)=O Chemical compound CC(C)(C)NS(c1cc(-c2c(cccc3-c4ccccc4N4Cc5ccccn5)c3c4nn2)cnc1)(=O)=O KBUQCQMKINPEAI-UHFFFAOYSA-N 0.000 description 1
- TZLLDSUEDWNDHY-UHFFFAOYSA-N CC(C)(C)NS(c1cncc(-c(nn2)c(cccc3-c4ccccc4)c3c2Cl)c1)(=O)=O Chemical compound CC(C)(C)NS(c1cncc(-c(nn2)c(cccc3-c4ccccc4)c3c2Cl)c1)(=O)=O TZLLDSUEDWNDHY-UHFFFAOYSA-N 0.000 description 1
- LEYCMXGHLQMWOV-UHFFFAOYSA-N CC(C1)C=NC=C1c1c(cccc2-c3ccccc3)c2c(NCCc2ccccc2)nn1 Chemical compound CC(C1)C=NC=C1c1c(cccc2-c3ccccc3)c2c(NCCc2ccccc2)nn1 LEYCMXGHLQMWOV-UHFFFAOYSA-N 0.000 description 1
- DAISWHFZWZZBBD-UHFFFAOYSA-N CC1(C)OB(c2cncc(N)c2)OC1(C)C Chemical compound CC1(C)OB(c2cncc(N)c2)OC1(C)C DAISWHFZWZZBBD-UHFFFAOYSA-N 0.000 description 1
- FAUUUFTWZDHEHH-NASUQTAISA-N CNS(c1cc(C(C(CC=C2)C3=C2c2ccccc2)=NN=C3N[C@@H](c2ccccc2)N)cnc1)(=O)=O Chemical compound CNS(c1cc(C(C(CC=C2)C3=C2c2ccccc2)=NN=C3N[C@@H](c2ccccc2)N)cnc1)(=O)=O FAUUUFTWZDHEHH-NASUQTAISA-N 0.000 description 1
- SZBFBCQTUVCDMV-UHFFFAOYSA-N Cc1c(c(-c2ccccc2)ccc2)c2c(-c2cc(N)cnc2)nn1 Chemical compound Cc1c(c(-c2ccccc2)ccc2)c2c(-c2cc(N)cnc2)nn1 SZBFBCQTUVCDMV-UHFFFAOYSA-N 0.000 description 1
- BKZBCSLLXRVZNI-UHFFFAOYSA-N Clc(c1cccc(-c2ccccc2)c11)nnc1Cl Chemical compound Clc(c1cccc(-c2ccccc2)c11)nnc1Cl BKZBCSLLXRVZNI-UHFFFAOYSA-N 0.000 description 1
- YWYFBELYNCKKGN-UHFFFAOYSA-N NS(c1cncc(-c2c(cccc3-c4ccccc4)c3c(NCC3=CC(C(F)(F)F)=CCC3)nn2)c1)(O)=O Chemical compound NS(c1cncc(-c2c(cccc3-c4ccccc4)c3c(NCC3=CC(C(F)(F)F)=CCC3)nn2)c1)(O)=O YWYFBELYNCKKGN-UHFFFAOYSA-N 0.000 description 1
- IXTRNHBDBHNMOW-UHFFFAOYSA-N O=Sc1cncc(-c2c(cccc3-c4ccccc4)c3c(NCc3cc(Cl)cc(Cl)c3)nn2)c1 Chemical compound O=Sc1cncc(-c2c(cccc3-c4ccccc4)c3c(NCc3cc(Cl)cc(Cl)c3)nn2)c1 IXTRNHBDBHNMOW-UHFFFAOYSA-N 0.000 description 1
- LVNOFDWKIMBXSB-UHFFFAOYSA-N OC(c1cncc(C(c2c3c(-c4ccccc4)ccc2)=NNC3NCc2ccccn2)c1)NC(CCC1)C1OCc1ccccc1 Chemical compound OC(c1cncc(C(c2c3c(-c4ccccc4)ccc2)=NNC3NCc2ccccn2)c1)NC(CCC1)C1OCc1ccccc1 LVNOFDWKIMBXSB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361775748P | 2013-03-11 | 2013-03-11 | |
| US61/775,748 | 2013-03-11 | ||
| US14/200,063 US9242966B2 (en) | 2013-03-11 | 2014-03-07 | Phthalazines as potassium ion channel inhibitors |
| US14/200,063 | 2014-03-07 | ||
| PCT/US2014/022252 WO2014143608A1 (en) | 2013-03-11 | 2014-03-10 | Phthalazines as potassium ion channel inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016514129A JP2016514129A (ja) | 2016-05-19 |
| JP2016514129A5 JP2016514129A5 (cg-RX-API-DMAC7.html) | 2017-04-13 |
| JP6427164B2 true JP6427164B2 (ja) | 2018-11-21 |
Family
ID=50382740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016500926A Expired - Fee Related JP6427164B2 (ja) | 2013-03-11 | 2014-03-10 | カリウムイオンチャネル阻害剤としてのフタラジン |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9242966B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2970179A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6427164B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN105073724A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014143608A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR091402A1 (es) * | 2012-06-11 | 2015-02-04 | Bristol Myers Squibb Co | Profarmacos de acido fosforadimico |
| US9403834B2 (en) | 2013-03-11 | 2016-08-02 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| WO2014143609A1 (en) | 2013-03-11 | 2014-09-18 | Bristol-Myers Squibb Company | Isoquinolines as potassium ion channel inhibitors |
| JP6386527B2 (ja) | 2013-03-11 | 2018-09-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | カリウムイオンチャネル阻害剤としてのピロロピリダジン |
| WO2016021742A1 (en) * | 2014-08-07 | 2016-02-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds as ep4 receptor antagonists |
| US20180093956A1 (en) * | 2015-02-06 | 2018-04-05 | Abbvie Inc. | Substituted phthalazines |
| CN105669678B (zh) * | 2016-03-08 | 2017-11-03 | 中国农业大学 | 一种酞嗪并吡咯类化合物及其制备方法 |
| CN115894416B (zh) * | 2022-12-02 | 2024-07-19 | 大连新阳光材料科技有限公司 | 一种选择性制备2,3,3`,4`-联苯四甲酸二酐的方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| US6331543B1 (en) | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| NZ508118A (en) | 1998-07-06 | 2003-07-25 | Bristol Myers Squibb Co | Heteroaryl substituted biphenyl sulfonamides useful as dual angiotensin endothelin receptor antogonists |
| US6576644B2 (en) * | 2000-09-06 | 2003-06-10 | Bristol-Myers Squibb Co. | Quinoline inhibitors of cGMP phosphodiesterase |
| US6599685B1 (en) | 2002-01-08 | 2003-07-29 | Eastman Kodak Company | Thermally developable imaging materials having improved shelf stability and stabilizing compositions |
| CL2004000409A1 (es) * | 2003-03-03 | 2005-01-07 | Vertex Pharma | Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu |
| EP1454908B1 (en) | 2003-03-07 | 2008-02-27 | Sanofi-Aventis | Substituted pyridinyl-2-(diaza-bicyclo-alkyl)-pyrimidinone derivatives |
| EP1454910A1 (en) | 2003-03-07 | 2004-09-08 | Sanofi-Synthelabo | Substituted pyrimidinyl-2-(diaza-bicyclo-alkyl)-pyrimidone derivatives |
| EP1667979A4 (en) * | 2003-09-23 | 2007-04-18 | Merck & Co Inc | ISOCHINOLINE AS KALIUM CHANNEL INHIBITORS |
| WO2005121157A1 (en) | 2004-06-09 | 2005-12-22 | Sumitomo Chemical Company, Limited | Monophosphine compounds, transition metal complexes thereof and production of optically active compounds using the complexes as asymmetric catalysts |
| JP2008517933A (ja) * | 2004-10-26 | 2008-05-29 | ノバルティス アクチエンゲゼルシャフト | ｃ−ＪＵＮＮ末端キナーゼ（ＪＮＫ）およびＰ−３８キナーゼ阻害剤としての、ピロロ［１，２−Ｄ］［１，２−４］トリアジン |
| CN101115736A (zh) * | 2005-03-14 | 2008-01-30 | 神经研究公司 | 钾通道调节剂和它们的医药用途 |
| US8252806B2 (en) | 2005-03-14 | 2012-08-28 | Neurosearch A/S | Potassium channel modulating agents and their medical use |
| US7683066B2 (en) | 2005-05-20 | 2010-03-23 | Vertex Pharmaceuticals Incorporated | Isoquinolines useful as modulators of ion channels |
| NZ579890A (en) | 2007-03-20 | 2012-05-25 | Celgene Corp | 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same |
| TWI488851B (zh) | 2009-09-03 | 2015-06-21 | 必治妥美雅史谷比公司 | 作為鉀離子通道抑制劑之喹唑啉 |
| WO2012075393A2 (en) | 2010-12-02 | 2012-06-07 | President And Fellows Of Harvard College | Activators of proteasomal degradation and uses thereof |
| US8642774B2 (en) | 2011-12-08 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Compounds |
-
2014
- 2014-03-07 US US14/200,063 patent/US9242966B2/en active Active
- 2014-03-10 JP JP2016500926A patent/JP6427164B2/ja not_active Expired - Fee Related
- 2014-03-10 CN CN201480013624.5A patent/CN105073724A/zh active Pending
- 2014-03-10 EP EP14713003.3A patent/EP2970179A1/en not_active Withdrawn
- 2014-03-10 WO PCT/US2014/022252 patent/WO2014143608A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20140303168A1 (en) | 2014-10-09 |
| JP2016514129A (ja) | 2016-05-19 |
| WO2014143608A1 (en) | 2014-09-18 |
| US9242966B2 (en) | 2016-01-26 |
| EP2970179A1 (en) | 2016-01-20 |
| CN105073724A (zh) | 2015-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6427164B2 (ja) | カリウムイオンチャネル阻害剤としてのフタラジン | |
| JP6427551B2 (ja) | カリウムイオンチャネル阻害剤としてのピロロトリアジン | |
| JP5950978B2 (ja) | カリウムイオンチャネルインヒビターとしてのキナゾリン | |
| CN104513239B (zh) | 吡唑并[3,4‑c]吡啶‑7‑酮类化合物及其应用 | |
| JP6386527B2 (ja) | カリウムイオンチャネル阻害剤としてのピロロピリダジン | |
| WO2023232069A1 (zh) | 一种氮杂喹啉酮类衍生物、其制备方法及用途 | |
| JP2016516691A (ja) | カリウムイオンチャネル阻害剤としてのイソキノリン | |
| JP6395798B2 (ja) | カリウムイオンチャネル阻害剤としてのピロロトリアジン | |
| CN113880804A (zh) | 新型苯并咪唑化合物 | |
| CN114671856B (zh) | 多取代的尿嘧啶衍生物及其用途 | |
| WO2022135534A1 (zh) | 取代的含氮双环化合物及其用途 | |
| TW201514162A (zh) | 作爲鉀離子通道抑制劑之呔 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20160219 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170308 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170308 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180508 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180807 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180821 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181001 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181023 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181026 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6427164 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |